FINNENCE ▪ THE WIRE FILE
THE WIRE · № 73121
News■ Unclear/unknown
Roundup: TRexBio & Retension Pharmaceuticals Announce IPO Pricing
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-10-09 13:53 UTC
LAST UPDATE2026-10-09 13:53 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Two biotech IPO pricings signal selective new-issue demand but no broad market driver.
Biotech IPO pricings show selective demand
CATALYST TO WATCH
Aftermarket trading performance
MAIN RISK
Weak aftermarket could chill issuance
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
←CORRELATIONshares Healthcare
Iambic sets IPO terms, seeking $150 million to advance AI-designed cancer drugs2026-10-09 11:15 UTC
Iambic sets IPO terms, seeking $150 million to advance AI-designed cancer drugs2026-10-09 11:15 UTC
←CORRELATIONshares Healthcare
New Phase 3 trial: Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2) — Viking Therapeutics, Inc.2026-10-09 12:00 UTC
New Phase 3 trial: Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2) — Viking Therapeutics, Inc.2026-10-09 12:00 UTC
←CORRELATIONshares Healthcare
New Phase 3 trial: A Study to Learn About the Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe Asthma — Pfizer2026-10-09 12:00 UTC
New Phase 3 trial: A Study to Learn About the Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe Asthma — Pfizer2026-10-09 12:00 UTC
←CORRELATIONshares Healthcare
New Phase 3 trial: Phase 3 Study of Intravitreal 4D-150 in Adults With Diabetic Macular Edema (DME) (4D-150-C005) — 4D Molecular Therapeutics2026-10-09 12:00 UTC
New Phase 3 trial: Phase 3 Study of Intravitreal 4D-150 in Adults With Diabetic Macular Edema (DME) (4D-150-C005) — 4D Molecular Therapeutics2026-10-09 12:00 UTC
←CORRELATIONshares Healthcare
New Phase 3 trial: Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) Tablets — Trevi Therapeutics2026-10-09 12:00 UTC
New Phase 3 trial: Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) Tablets — Trevi Therapeutics2026-10-09 12:00 UTC
←CORRELATIONshares Healthcare
Phase 3 results posted: Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) — Sanofi2026-10-09 12:00 UTC
Phase 3 results posted: Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) — Sanofi2026-10-09 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.